{"format":{"id":"oncolytic-virus","name":"Oncolytic viruses","blurb":"A virus backbone edited to replicate only in tumour cells and a transgene it carries to call the immune system in.","axes":["virus","transgene"],"axisLabels":["Virus backbone","Transgene"],"components":[{"key":"virus","label":"Virus backbone"},{"key":"transgene","label":"Transgene"}]},"counts":{"approved":2,"development":2,"stopped":0,"unclear":0,"untried":2,"drugs":5,"partial":0,"unresolved":3},"coverage":{"total":8,"full":5,"partial":0,"unresolved":3,"pct":63},"rows":[{"key":"virus","id":"hsv-1","name":"Herpes simplex virus 1","href":"/technologies/oncolytic-virus/"},{"key":"virus","id":"adenovirus","name":"Adenovirus","href":"/technologies/oncolytic-virus/"}],"cols":[{"key":"transgene","id":"gm-csf","name":"GM-CSF"},{"key":"transgene","id":"anti-pd1","name":"Anti-PD-1"},{"key":"transgene","id":"none-stated","name":"No transgene stated (deletion-based selectivity)"}],"cells":[{"a":{"key":"virus","id":"hsv-1","name":"Herpes simplex virus 1","href":"/technologies/oncolytic-virus/"},"b":{"key":"transgene","id":"gm-csf","name":"GM-CSF"},"state":"approved","drugs":[{"id":"talimogene-laherparepvec","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","state":"approved","status":"approved"},{"id":"vusolimogene-oderparepvec","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"talimogene-laherparepvec","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/talimogene-laherparepvec/"},{"record":"talimogene-laherparepvec","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Unresectable melanoma with injectable lesions","href":"/drugs/talimogene-laherparepvec/"},{"record":"talimogene-laherparepvec","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"talimogene-laherparepvec","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic"},{"record":"talimogene-laherparepvec","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Imlygic"},{"record":"talimogene-laherparepvec","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Imlygic"},{"record":"registry:talimogene-laherparepvec","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/talimogene-laherparepvec/#registry"},{"record":"vusolimogene-oderparepvec","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vusolimogene-oderparepvec/"},{"record":"vusolimogene-oderparepvec","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)","href":"/drugs/vusolimogene-oderparepvec/"},{"record":"vusolimogene-oderparepvec","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"vusolimogene-oderparepvec","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2025-07-22: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"Complete response letter citing trial design and heterogeneity"},{"record":"nct06898970","field":"status","kind":"trial","state":"development","label":"Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma: phase 2, recruiting","href":"/trials/nct06898970/"},{"record":"nct06264180","field":"status","kind":"trial","state":"development","label":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]: phase 3, recruiting","href":"/trials/nct06264180/"},{"record":"registry:vusolimogene-oderparepvec","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/vusolimogene-oderparepvec/#registry"}],"reasons":[{"drugId":"vusolimogene-oderparepvec","drugName":"Vusolimogene oderparepvec","drugRoute":"/drugs/vusolimogene-oderparepvec/","drugState":"approved","record":"vusolimogene-oderparepvec","kind":"event","label":"US 2025-07-22: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"Complete response letter citing trial design and heterogeneity"}]},{"a":{"key":"virus","id":"hsv-1","name":"Herpes simplex virus 1","href":"/technologies/oncolytic-virus/"},"b":{"key":"transgene","id":"anti-pd1","name":"Anti-PD-1"},"state":"development","drugs":[{"id":"t3011","name":"T3011","route":"/drugs/t3011/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"t3011","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/t3011/"},{"record":"nct04370587","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva: phase 1/2, recruiting","href":"/trials/nct04370587/"},{"record":"nct06971614","field":"status","kind":"trial","state":"development","label":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC: phase 2, recruiting","href":"/trials/nct06971614/"},{"record":"registry:t3011","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/t3011/#registry"}],"reasons":[]},{"a":{"key":"virus","id":"adenovirus","name":"Adenovirus","href":"/technologies/oncolytic-virus/"},"b":{"key":"transgene","id":"gm-csf","name":"GM-CSF"},"state":"development","drugs":[{"id":"cretostimogene","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"cretostimogene","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/cretostimogene/"},{"record":"nct06111235","field":"status","kind":"trial","state":"development","label":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT: phase 3, active","href":"/trials/nct06111235/"},{"record":"nct06567743","field":"status","kind":"trial","state":"development","label":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC: phase 2, recruiting","href":"/trials/nct06567743/"},{"record":"nct07283835","field":"status","kind":"trial","state":"development","label":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin: phase 2, recruiting","href":"/trials/nct07283835/"},{"record":"registry:cretostimogene","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/cretostimogene/#registry"}],"reasons":[]},{"a":{"key":"virus","id":"adenovirus","name":"Adenovirus","href":"/technologies/oncolytic-virus/"},"b":{"key":"transgene","id":"none-stated","name":"No transgene stated (deletion-based selectivity)"},"state":"approved","drugs":[{"id":"h101-oncolytic-adenovirus","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"h101-oncolytic-adenovirus","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/h101-oncolytic-adenovirus/"},{"record":"h101-oncolytic-adenovirus","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2005: Late-stage nasopharyngeal carcinoma, with chemotherapy","href":"/drugs/h101-oncolytic-adenovirus/"},{"record":"h101-oncolytic-adenovirus","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2005","href":"https://english.nmpa.gov.cn/"},{"record":"nct07398664","field":"status","kind":"trial","state":"development","label":"H101 Plus TACE for r/m HNSCC: phase 2, recruiting","href":"/trials/nct07398664/"},{"record":"registry:h101-oncolytic-adenovirus","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/h101-oncolytic-adenovirus/#registry"}],"reasons":[]}],"components":{"virus":[{"key":"virus","id":"hsv-1","name":"Herpes simplex virus 1","href":"/technologies/oncolytic-virus/","count":3,"drugIds":["t3011","talimogene-laherparepvec","vusolimogene-oderparepvec"],"states":{"approved":2,"development":1,"stopped":0,"unclear":0}},{"key":"virus","id":"adenovirus","name":"Adenovirus","href":"/technologies/oncolytic-virus/","count":2,"drugIds":["cretostimogene","h101-oncolytic-adenovirus"],"states":{"approved":1,"development":1,"stopped":0,"unclear":0}}],"transgene":[{"key":"transgene","id":"gm-csf","name":"GM-CSF","count":3,"drugIds":["cretostimogene","talimogene-laherparepvec","vusolimogene-oderparepvec"],"states":{"approved":2,"development":1,"stopped":0,"unclear":0}},{"key":"transgene","id":"anti-pd1","name":"Anti-PD-1","count":1,"drugIds":["t3011"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"transgene","id":"none-stated","name":"No transgene stated (deletion-based selectivity)","count":1,"drugIds":["h101-oncolytic-adenovirus"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}]},"drugs":[{"id":"cretostimogene","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/","status":"phase-3","modality":"Oncolytic adenovirus (intravesical)","state":"development","confidence":"high","fields":["modality","mechanism","name"],"components":{"virus":{"id":"adenovirus","name":"Adenovirus","href":"/technologies/oncolytic-virus/","confidence":"high","from":["modality","mechanism","name"],"detail":null},"transgene":{"id":"gm-csf","name":"GM-CSF","href":null,"confidence":"high","from":["mechanism"],"detail":null}},"evidence":[{"record":"cretostimogene","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/cretostimogene/"},{"record":"nct06111235","field":"status","kind":"trial","state":"development","label":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT: phase 3, active","href":"/trials/nct06111235/"},{"record":"nct06567743","field":"status","kind":"trial","state":"development","label":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC: phase 2, recruiting","href":"/trials/nct06567743/"},{"record":"nct07283835","field":"status","kind":"trial","state":"development","label":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin: phase 2, recruiting","href":"/trials/nct07283835/"},{"record":"registry:cretostimogene","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/cretostimogene/#registry"}],"reasons":[]},{"id":"h101-oncolytic-adenovirus","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/","status":"approved","modality":"Oncolytic virus (E1B-deleted adenovirus)","state":"approved","confidence":"medium","fields":["modality","mechanism","name"],"components":{"virus":{"id":"adenovirus","name":"Adenovirus","href":"/technologies/oncolytic-virus/","confidence":"high","from":["modality","mechanism","name"],"detail":null},"transgene":{"id":"none-stated","name":"No transgene stated (deletion-based selectivity)","href":null,"confidence":"medium","from":["mechanism"],"detail":null}},"evidence":[{"record":"h101-oncolytic-adenovirus","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/h101-oncolytic-adenovirus/"},{"record":"h101-oncolytic-adenovirus","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2005: Late-stage nasopharyngeal carcinoma, with chemotherapy","href":"/drugs/h101-oncolytic-adenovirus/"},{"record":"h101-oncolytic-adenovirus","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2005","href":"https://english.nmpa.gov.cn/"},{"record":"nct07398664","field":"status","kind":"trial","state":"development","label":"H101 Plus TACE for r/m HNSCC: phase 2, recruiting","href":"/trials/nct07398664/"},{"record":"registry:h101-oncolytic-adenovirus","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/h101-oncolytic-adenovirus/#registry"}],"reasons":[]},{"id":"t3011","name":"T3011","route":"/drugs/t3011/","status":"phase-2","modality":"oncolytic virus (intratumoral oncolytic HSV-1, per the sponsor's pipeline page; registered as a drug on ClinicalTrials.gov)","state":"development","confidence":"high","fields":["modality","mechanism","name"],"components":{"virus":{"id":"hsv-1","name":"Herpes simplex virus 1","href":"/technologies/oncolytic-virus/","confidence":"high","from":["modality","mechanism","name"],"detail":null},"transgene":{"id":"anti-pd1","name":"Anti-PD-1","href":null,"confidence":"high","from":["mechanism"],"detail":null}},"evidence":[{"record":"t3011","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/t3011/"},{"record":"nct04370587","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva: phase 1/2, recruiting","href":"/trials/nct04370587/"},{"record":"nct06971614","field":"status","kind":"trial","state":"development","label":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC: phase 2, recruiting","href":"/trials/nct06971614/"},{"record":"registry:t3011","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/t3011/#registry"}],"reasons":[]},{"id":"talimogene-laherparepvec","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","status":"approved","modality":"Oncolytic virus (HSV-1)","state":"approved","confidence":"high","fields":["modality","mechanism","name"],"components":{"virus":{"id":"hsv-1","name":"Herpes simplex virus 1","href":"/technologies/oncolytic-virus/","confidence":"high","from":["modality","mechanism","name"],"detail":null},"transgene":{"id":"gm-csf","name":"GM-CSF","href":null,"confidence":"high","from":["mechanism"],"detail":null}},"evidence":[{"record":"talimogene-laherparepvec","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/talimogene-laherparepvec/"},{"record":"talimogene-laherparepvec","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Unresectable melanoma with injectable lesions","href":"/drugs/talimogene-laherparepvec/"},{"record":"talimogene-laherparepvec","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"talimogene-laherparepvec","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic"},{"record":"talimogene-laherparepvec","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Imlygic"},{"record":"talimogene-laherparepvec","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Imlygic"},{"record":"registry:talimogene-laherparepvec","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/talimogene-laherparepvec/#registry"}],"reasons":[]},{"id":"vusolimogene-oderparepvec","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","status":"approved","modality":"Oncolytic virus (HSV-1)","state":"approved","confidence":"high","fields":["modality","mechanism","name"],"components":{"virus":{"id":"hsv-1","name":"Herpes simplex virus 1","href":"/technologies/oncolytic-virus/","confidence":"high","from":["modality","mechanism","name"],"detail":null},"transgene":{"id":"gm-csf","name":"GM-CSF","href":null,"confidence":"high","from":["mechanism"],"detail":null}},"evidence":[{"record":"vusolimogene-oderparepvec","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vusolimogene-oderparepvec/"},{"record":"vusolimogene-oderparepvec","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)","href":"/drugs/vusolimogene-oderparepvec/"},{"record":"vusolimogene-oderparepvec","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"vusolimogene-oderparepvec","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2025-07-22: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"Complete response letter citing trial design and heterogeneity"},{"record":"nct06898970","field":"status","kind":"trial","state":"development","label":"Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma: phase 2, recruiting","href":"/trials/nct06898970/"},{"record":"nct06264180","field":"status","kind":"trial","state":"development","label":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]: phase 3, recruiting","href":"/trials/nct06264180/"},{"record":"registry:vusolimogene-oderparepvec","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/vusolimogene-oderparepvec/#registry"}],"reasons":[{"drugId":"vusolimogene-oderparepvec","drugName":"Vusolimogene oderparepvec","drugRoute":"/drugs/vusolimogene-oderparepvec/","drugState":"approved","record":"vusolimogene-oderparepvec","kind":"event","label":"US 2025-07-22: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"Complete response letter citing trial design and heterogeneity"}]}],"unresolved":[{"id":"olvimulogene-nanivacirepvec","name":"Olvimulogene nanivacirepvec","route":"/drugs/olvimulogene-nanivacirepvec/","format":"oncolytic-virus","modality":"oncolytic virus","missing":["virus","transgene"],"why":"No virus backbone on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"theo-260","name":"THEO-260","route":"/drugs/theo-260/","format":"oncolytic-virus","modality":"Oncolytic virus","missing":["virus","transgene"],"why":"No virus backbone on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"tilt-123","name":"TILT-123","route":"/drugs/tilt-123/","format":"oncolytic-virus","modality":"Oncolytic virus","missing":["virus","transgene"],"why":"No virus backbone on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."}],"stopped":[{"drugId":"vusolimogene-oderparepvec","drugName":"Vusolimogene oderparepvec","drugRoute":"/drugs/vusolimogene-oderparepvec/","drugState":"approved","record":"vusolimogene-oderparepvec","kind":"event","label":"US 2025-07-22: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"Complete response letter citing trial design and heterogeneity"}],"proposed":[],"note":"Every state is derived from the records named in evidence; untried means no medicine in this corpus combines the two parts. Proposed cells are hypotheses from the open pipeline (docs/OPEN-PIPELINE.md), not records of a medicine. CC BY-NC 4.0, attribute Data from OnCo (onco.cc). Not medical advice."}